证券代码：000166 证券简称：申万宏源 公告编号：临2025-77 申万宏源集团股份有限公司董事会 二〇二五年九月二十四日 公司所属子公司申万宏源证券有限公司于 2023 年 9 月 21 日发行 申万宏源证券有限公司 2023 年面向专业投资者公开发行公司债券 （第四期）（品种一）（以下简称"本期债券"），发行规模人民币 28 亿元，票面利率 2.80%，期限 2 年，债券代码 148467，债券简称 23 申证 07。（相关情况请详见公司于 2023 年 9 月 23 日在《中国证 券报》《证券时报》《上海证券报》和巨潮资讯网 www.cninfo.com.cn 上刊登的公告） 本期债券兑付日为2025年9月22日，摘牌日为2025年9月22日，申 万宏源证券有限公司已按照《申万宏源证券有限公司2023年面向专业 投资者公开发行公司债券（第四期）募集说明书》相关约定，完成本 期债券本息兑付并予以摘牌。 申 万 宏 源 集 团 股 份 有 限 公 司 关于申万宏源证券有限公司 2023 年面向专业投资者公开 发行公司债券（第四期）（品种一）本息兑付 并摘牌的公告 特此公告。 本公司及董事会全体成员保证信 ...

Core Viewpoint - The construction materials industry is expected to see a narrowing revenue decline and profit improvement in the first half of 2025, with notable performances in the cement and fiberglass sectors [1] Group 1: Cement Industry - The cement industry achieved a total revenue of 118.8 billion yuan in the first half of 2025, a year-on-year decline of 7.5%, but with a net profit of 5.4 billion yuan, reflecting a significant year-on-year increase of 1110.5% [2][1] - The improvement in cement industry profits is partly due to a low base from the previous year and better pricing conditions, along with a decrease in coal costs compared to the same period last year [2] Group 2: Fiberglass Industry - The fiberglass sector reported a total revenue of 31.1 billion yuan in the first half of 2025, representing a year-on-year growth of 20.9%, with a net profit of 3.29 billion yuan, up 127.0% year-on-year [3] - The profit improvement in the fiberglass industry is attributed to the pricing recovery initiated by leading companies since 2024, which is now beginning to show results [3] Group 3: Consumer Building Materials - The consumer building materials segment recorded a revenue of 68.76 billion yuan in the first half of 2025, down 2.7% year-on-year, with a net profit of 4.35 billion yuan, a decline of 13.2% [4] - Companies like Keda Manufacturing and Sankeshu are showing strong performance due to overseas market strategies and unique channel advantages, respectively [4] Group 4: Glass Industry - The glass industry faced challenges, achieving a revenue of 24.6 billion yuan in the first half of 2025, down 17.0% year-on-year, with a net profit of 1 billion yuan, a decline of 60.3% [5] - The photovoltaic glass sector experienced temporary recovery, but overall profitability is under pressure due to high base effects from the previous year and weak demand in the construction glass market [5] Group 5: Early Cycle Industries - Early cycle sectors remain under pressure, with profitability constrained by cement price recovery, although leading companies like Subote have reported revenue and profit growth [6] - Subote has expanded its efforts in major engineering projects in the western regions, achieving significant results in water, nuclear power, and railway sectors [6] Group 6: Investment Recommendations - Investment opportunities are suggested in the fiberglass and cement sectors, focusing on companies with strong profit recovery and growth expectations [7] - Recommended companies include leading players in the cement sector such as Huaxin Cement, Conch Cement, and Shangfeng Cement, as well as fiberglass companies like China Jushi and Zhongcai Technology [7]

Group 1 - The core viewpoint is that in H1 2025, the cosmetics retail sales growth has reversed its decline, achieving a growth rate of 2.9% due to consumption-boosting policies and improved income expectations [1][2] - The demand for cosmetics is expected to remain strong in H2 2025, with the off-peak season in July and August showing increased growth, indicating positive demand expectations [1][2] - The competitive landscape is improving, with domestic brands making significant progress, and leading domestic brands are now sharing market share equally with international brands [2] Group 2 - In the cosmetics sector, the revenue growth rate for key covered companies in H1 2025 is around 8%, with net profit growth slightly lower than revenue growth [2] - Specific companies in the cosmetics sector include: - Shiseido: H1 2025 revenue of 4.11 billion yuan, up 17.3%, net profit of 520 million yuan, up 30.6% [2] - Proya: H1 2025 revenue of 5.36 billion yuan, up 7.2%, net profit of 800 million yuan, up 13.8% [2] - Water Sheep: H1 2025 revenue of 2.5 billion yuan, up 9.0%, net profit of 123 million yuan, up 16.5% [2] - Marubi: H1 2025 revenue of 1.77 billion yuan, up 30.8%, net profit of 190 million yuan, up 5.2% [2] Group 3 - The second category of companies is capitalizing on consumer trends, with notable performances including: - Mao Geping: H1 2025 revenue of 2.59 billion yuan, up 31.3%, net profit of 670 million yuan, up 36.1% [3] - Juzi Biotechnology: H1 2025 revenue of 3.11 billion yuan, up 22.5%, net profit of 1.18 billion yuan, up 20.2% [3] - The third category includes companies showing marginal improvements or initial signs of strategic transformation, such as Shanghai Jahwa, Huaxi Biological, and Betaini [3] Group 4 - In the personal care sector, two companies reported revenue and net profit growth, indicating a strong market potential: - RuYuchen: H1 2025 revenue of 1.32 billion yuan, up 67.6%, net profit of 70 million yuan, up 85.6% [3] - Runben: H1 2025 revenue of 900 million yuan, up 20.3%, net profit of 190 million yuan, up 4.2% [3] Group 5 - In the medical beauty sector, the performance is mixed, with some companies experiencing declines: - Aimeike: H1 2025 revenue of 1.3 billion yuan, down 21.6%, net profit of 790 million yuan, down 29.6% [4] - Langzi: H1 2025 revenue of 2.79 billion yuan, down 4.3%, net profit of 270 million yuan, up 64.1% [4] - Overall, the medical beauty sector reported a revenue of 1.333 billion yuan, down 6.1%, with a gross margin of 54.54% [4]

Group 1 - The article announces the launch of the 2026 autumn campus recruitment by Shenwan Hongyuan Research, emphasizing the company's commitment to nurturing talent and building a long-term professional research team [5][7]. - Shenwan Hongyuan Research, established in 1992, is one of the earliest and largest comprehensive securities research institutions in mainland China, focusing on a wide range of investment research areas including macroeconomics, industry analysis, and investment strategies [7]. - The recruitment aims to attract graduates from both domestic and overseas institutions, specifically those graduating between January 1, 2026, and July 31, 2026, for domestic schools, and between May 1, 2025, and July 31, 2026, for overseas schools [14]. Group 2 - The company offers a comprehensive training program that combines innovative and traditional skills, providing a structured progression for talent development [9]. - New employees will receive mentorship from experienced staff, facilitating their integration into the company and enhancing their professional growth [10]. - Various positions are available, including macroeconomic analysts, bond analysts, strategy analysts, and industry research analysts, indicating a diverse range of opportunities for prospective candidates [11].

Core Viewpoint - The article provides information on the holiday trading schedule for the 2025 National Day and Mid-Autumn Festival, emphasizing the opportunities for investors to utilize idle funds through government bond reverse repos during the holiday period [5][9]. Trading Schedule - The A-shares market will be closed from October 1 (Wednesday) to October 8 (Wednesday), reopening on October 9 (Thursday) [5]. - The Hong Kong Stock Connect will also be unavailable from October 1 to October 8, resuming on October 9 [5]. Government Bond Reverse Repo - Government bond reverse repos are described as short-term loans where individuals lend their funds to earn fixed interest, with government bonds used as collateral [9]. - The safety and yield of government bond reverse repos are highlighted, especially during month-end, quarter-end, year-end, and pre-holiday periods when rates tend to rise [9]. - The minimum investment threshold for participating in government bond reverse repos is set at 1,000 yuan [13]. Interest Calculation - The interest calculation period is defined as the actual number of days the funds are occupied, from the first settlement date to the maturity date [10]. - Specific interest calculation days for various terms are provided, indicating the potential earnings during the holiday [11][14]. Participation Pathways - Investors can participate in government bond reverse repos through the Shenwan Hongyuan Securities APP, with clear instructions on accessing the relevant sections for trading [12][16]. - The article encourages investors to consider different term products based on their yield and personal financial needs [13]. Investment Tips - Investors are advised to operate a one-day reverse repo two trading days before the holiday to maximize holiday earnings without affecting other trading activities [13]. - The article suggests selecting higher-yielding products when different term products have the same interest calculation days [13].

Core Viewpoint - The report from Shenwan Hongyuan indicates that Sunshine Insurance (06963) is expected to achieve a net profit attributable to shareholders of 5.734 billion, 6.056 billion, and 6.788 billion yuan for the years 2025-2027, reflecting year-on-year growth of 5.2%, 5.6%, and 12.1% respectively, with a revised company valuation of 57.3 billion yuan and a target price of 5.35 HKD per share, maintaining a "Buy" rating [1] Group 1 - The company is projected to have a stable profit growth with a balanced asset-liability performance, and a dividend yield that ranks among the top in the industry. The net profit attributable to shareholders is expected to increase by 45.8% year-on-year to 5.449 billion yuan in 2024, with a 7.8% year-on-year increase to 3.389 billion yuan in the first half of 2025 [2] - The company emphasizes shareholder returns, with a dividend payout ratio expected to reach 40.1% in 2024, the highest among listed insurance companies, and a calculated dividend yield of 5.4% as of September 22, ranking second in the industry [2] Group 2 - The company has shown strong resilience and growth in its individual insurance performance, with a year-on-year increase in new business value (NBV) of 44.2% and 43.3% for 2023 and 2024 respectively, and a 47.3% increase to 4.008 billion yuan in the first half of 2025, leading the industry [3] - The bancassurance channel remains a traditional strength for the company, benefiting significantly from the "reporting and operation integration," with channel NBV growth of 43.6% and 53.0% for 2024 and the first half of 2025, contributing 60% of the total NBV [3] Group 3 - The company has seen a significant decline in liability costs, with a high proportion of new liabilities, and is expected to optimize the cost of existing liabilities. The NBV to effective business value ratio is projected to be 12.79% in 2024, ranking third among listed insurance companies [4] - The net investment yield and the difference between NBV and VIF yield are expected to improve, with year-on-year increases of 100 basis points and 31 basis points respectively, indicating a favorable trend in interest margins [4] - The company has increased its equity allocation in the secondary market, with a stock allocation ratio of 15.1% as of June, and a significant portion of FVOCI stocks exceeding 70%, indicating a stable performance compared to peers [4]

Core Viewpoint - The report from Shenwan Hongyuan indicates that Zai Lab (09688) is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Lab from 2025 to 2027 are estimated at $553 million, $802 million, and $1.203 billion respectively, with net profit attributable to the parent company expected to be -$134 million, $15 million, and $173 million for the same years [1] - The target price set at HKD 35.2 implies a 39% upside potential, reflecting confidence in the company's innovative pipeline [1] Product Portfolio and Commercialization - Zai Lab is a global biopharmaceutical company in the commercialization stage, with seven products approved in China, including four oncology products and one immunology product [2] - Since the approval of its first commercial product, Niraparib, in 2019, Zai Lab has seen significant sales growth, with total revenue projected to reach $399 million in 2024, a 50% increase year-on-year [3] New Product Development - The company has submitted applications for new products, including KarXT and TF ADC, to the NMPA, with plans to submit for Bemarituzumab for 1L gastric cancer in the second half of the year [3] - Zai Lab anticipates revenue could reach $2 billion by 2028, supported by the sales of existing products and the approval of new products [3] Expansion of Indications - Efgartigimod, the first FcRn antagonist globally, has received approvals for multiple indications, with sales expected to reach $94 million in 2024, reflecting an 835% year-on-year growth [4] - The company is exploring additional indications for Efgartigimod, which could broaden its market reach across various medical fields [4] Global Pipeline Development - Zai Lab is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies, with several products showing potential for first-in-class (FIC) or best-in-class (BIC) status [5] - The company plans to initiate global pivotal studies for ZL-1310, which has shown promising clinical activity and safety [5]

Core Viewpoint - Zai Ding Pharma is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Ding Pharma are $553 million, $802 million, and $1.203 billion for 2025, 2026, and 2027 respectively [1] - Net profit projections for the company are -$134 million, $15 million, and $173 million for 2025, 2026, and 2027 respectively [1] - The target price is set at HKD 35.2, indicating a potential upside of 39% [1] Product Portfolio and Pipeline - Zai Ding Pharma has seven products approved for sale in China, including four oncology products, one immunology product, and two infectious disease products [2] - The company has seen a 50% year-on-year revenue growth in 2024, reaching $399 million, primarily due to the sales increase of existing products [3] - New product applications have been submitted to NMPA, with expectations for further approvals in the near future [3] Key Product Developments - Efgartigimod (艾加莫德) is being explored for additional indications beyond its current approvals, with significant sales growth anticipated [4] - The product is expected to generate $94 million in domestic sales in 2024, reflecting an 835% increase [4] Global Pipeline Expansion - The company is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies [5] - ZL-1310 has received Fast Track designation from the FDA, with positive clinical data expected to be presented at the 2025 ASCO annual meeting [5] - The company plans to initiate global pivotal studies for ZL-1310 in the near future [5]

Core Viewpoint - The report from Shenwan Hongyuan indicates that Sunshine Insurance (06963) is expected to see a steady growth in net profit from 2025 to 2027, with projected figures of 5.734 billion, 6.056 billion, and 6.788 billion yuan respectively, reflecting year-on-year growth rates of 5.2%, 5.6%, and 12.1% [1] Group 1: Profit Growth and Dividend Policy - The company is projected to achieve a year-on-year net profit increase of 45.8% to 5.449 billion yuan in 2024, with a stable profit performance in the first half of 2025, showing a year-on-year growth of 7.8% to 3.389 billion yuan [2] - The dividend payout ratio is expected to reach 40.1% in 2024, ranking first among listed insurance companies, with a calculated dividend yield of 5.4% based on the closing price on September 22, placing it second in the industry [2] Group 2: New Business Value (NBV) and Distribution Channels - The company has demonstrated strong resilience and growth in its life insurance segment, with NBV growth rates of 44.2% and 43.3% for 2023 and 2024 respectively, and a year-on-year increase of 47.3% to 4.008 billion yuan in the first half of 2025, leading the industry [3] - The bancassurance channel remains a traditional strength for the company, benefiting significantly from the "reporting and operation integration," with channel NBV growth rates of 6.4 percentage points and 7.2 percentage points for 2024 and the first half of 2025 respectively [3] Group 3: Liability Costs and Investment Returns - The company has seen a significant decline in new liability costs, with the NBV to effective business value ratio at 12.79% in 2024, ranking third among listed insurance companies, which is expected to further dilute the cost of existing liabilities [4] - The net investment return rate and the difference between NBV and effective business value yield are projected to increase year-on-year by 100 basis points and 31 basis points respectively, indicating an expansion of the interest spread [4] Group 4: Equity Allocation and Performance Stability - As of the end of June, the company's equity allocation in the secondary market has increased by 1.28 percentage points to 15.1%, with a stock allocation level that continues to rise, reaching 14.1% by the end of 2024, and the proportion of FVOCI stocks exceeding 70.38% [5] - The company’s CSM has shown steady growth, with a year-on-year increase of 12.6% to 50.9 billion yuan by the end of 2024, maintaining a stable amortization rate of 8.45% [5]

Group 1 - The announcement from Guozhong Water indicated a change in the sponsor representative for its ongoing issuance supervision work, with Shenwan Hongyuan now responsible for this role [2] - The new sponsor representatives are Mr. Zhao Zhidan and Mr. Cai Ming [2] - This change is part of the company's efforts to ensure compliance and effective management of its issuance process [2]